Petros Pharmaceuticals, Inc. (PTPI) presents an extremely thin liquidation recovery posture as of December 31, 2025. Total assets of $5.16M are entirely current, dominated by cash of $5.14M at 100% recovery. Applying liquidation haircuts, adjusted asset recovery approximates $5.14M. Total liabilities at face value are $2.29M (all current), consisting of accounts payable of $84K, accrued liabilities of $143K, and a Series A Preferred Stock redemption liability of $2.07M (tagged as PayablePreferredStockRedeemed). Net liquidation recovery to equity is approximately $2.85M, consistent with MFFAIS CLV/LLV/OLV of $2.84M. There are no intangibles, no PP&E, no inventory, and no lease obligations on the surviving balance sheet following the ABC assignment of operating subsidiaries (Metuchen, Timm Medical, PTV) in June 2025 and the Vivus termination agreement in March 2025. The entity has been reduced to a shell holding cash and a minimal current liability stack. The Series A Preferred Stock overhang is effectively resolved: $2.07M payable to remaining holders is accrued at face value on the balance sheet and is the primary claim senior to equity in a liquidation scenario. The $0.9K residual warrant liability (Series B Warrants, 36,198 remaining) is de minimis. The NOL carryforward of $84.3M federal is fully valuation-allowanced and carries zero liquidation value. The going concern qualification issued in prior periods persists; the 10-K filing does not explicitly withdraw that qualification for year-end 2025, consistent with the Q3 2025 10-Q which stated insufficient liquidity for 12-month operations. The February 2025 public offering raised $9.6M gross ($8.5M net) and the ABC gain of $7.0M on disposal of net liabilities of subsidiaries substantially restructured the balance sheet since the Q3 2025 filing period. The deemed dividend activity ($41.6M for warrant repricing, $3.0M for Series A Warrant modification) is non-cash and does not affect liquidation recovery but explains the massive deficit increase to $111.3M. Delisting from Nasdaq occurred May 2025; shares now trade OTCID under PTPI. Filing discusses the ABC transaction and Vivus settlement in MD&A but does not separately XBRL-tag the gain on assignment or the Vivus settlement proceeds as discrete balance sheet items beyond GainLossOnDispositionOfAssets1.
▼ Community Notes